Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,356,910
  • Shares Outstanding, K 45,718
  • Annual Sales, $ 22,270 K
  • Annual Income, $ -40,470 K
  • EBIT $ -87 M
  • EBITDA $ -85 M
  • 60-Month Beta 0.61
  • Price/Sales 59.33
  • Price/Cash Flow N/A
  • Price/Book 15.75

Options Overview Details

View History
  • Implied Volatility 98.44% (+4.86%)
  • Historical Volatility 455.81%
  • IV Percentile 22%
  • IV Rank 10.30%
  • IV High 456.20% on 12/02/25
  • IV Low 57.37% on 01/22/25
  • Expected Move (DTE 21) 4.46 (15.03%)
  • Put/Call Vol Ratio 0.63
  • Today's Volume 3,227
  • Volume Avg (30-Day) 17,865
  • Put/Call OI Ratio 1.03
  • Today's Open Interest 122,705
  • Open Int (30-Day) 288,717
  • Expected Range 25.23 to 34.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.51
  • Number of Estimates 4
  • High Estimate -0.46
  • Low Estimate -0.55
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -218.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.22 +468.77%
on 11/28/25
40.37 -26.46%
on 12/03/25
+24.50 (+472.06%)
since 11/26/25
3-Month
4.30 +590.47%
on 11/25/25
40.37 -26.46%
on 12/03/25
+22.60 (+318.76%)
since 09/26/25
52-Week
4.30 +590.47%
on 11/25/25
40.37 -26.46%
on 12/03/25
+15.61 (+110.87%)
since 12/26/24

Most Recent Stories

More News
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing...

CAPR : 29.69 (+0.03%)
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing...

CAPR : 29.69 (+0.03%)
Capricor Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement...

CAPR : 29.69 (+0.03%)
This ‘Strong Buy’ Penny Stock Just More Than Quadrupled on Clinical Trial Results. Should You Buy It Here?

Capricorn Therapeutics stock soared after the biotech firm announced positive deramiocel Phase 3 trial results. But CAPR shares still have major risks tied to them heading into 2026.

CAPR : 29.69 (+0.03%)
Wall Street pulls near its all-time high

U.S. stocks rose near their record levels

NVDA : 190.53 (+1.02%)
$SPX : 6,929.94 (-0.03%)
DLTR : 123.95 (+1.59%)
MDB : 435.85 (+0.08%)
AEO : 26.36 (-1.09%)
$IUXX : 25,644.39 (-0.05%)
M : 22.47 (+0.67%)
SIG : 85.21 (-2.07%)
MSFT : 487.71 (-0.06%)
PG : 144.74 (+0.17%)
$DOWI : 48,710.97 (-0.04%)
MCHP : 64.94 (-0.64%)
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03...

CAPR : 29.69 (+0.03%)
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025

--Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development-- SAN DIEGO, Nov. 24, 2025...

CAPR : 29.69 (+0.03%)
Capricor: Q3 Earnings Snapshot

Capricor: Q3 Earnings Snapshot

CAPR : 29.69 (+0.03%)
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025) Pending the results of the topline data...

CAPR : 29.69 (+0.03%)
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development–  SAN DIEGO,...

CAPR : 29.69 (+0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 30.83
2nd Resistance Point 30.40
1st Resistance Point 30.05
Last Price 29.69
1st Support Level 29.27
2nd Support Level 28.84
3rd Support Level 28.49

See More

52-Week High 40.37
Last Price 29.69
Fibonacci 61.8% 26.59
Fibonacci 50% 22.33
Fibonacci 38.2% 18.08
52-Week Low 4.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar